Trial Profile

A Phase I Trial for the Evaluation of the Two-way Pharmacokinetic-pharmacodynamic (PD) Interaction of Gender Affirming Exogenous Estrogen (With Testosterone Suppression) on TDF/FTC PrEP in Transgender Women (TGW)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Estradiol; Iohexol; Leuprorelin
Indications HIV infections
Focus Pharmacokinetics

11 Jun 2025 Status changed from recruiting to completed.
07 Mar 2025 Planned End Date changed from 30 Jun 2025 to 30 Nov 2025.
07 Mar 2025 Planned primary completion date changed from 1 Mar 2025 to 1 Jul 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com